Clinical Trials Logo

Ocular Surface Disease clinical trials

View clinical trials related to Ocular Surface Disease.

Filter by:

NCT ID: NCT05528016 Completed - Dry Eye Clinical Trials

Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate the short and long-term effects of skin-only and skin+muscle excision blepharoplasty on corneal nerves, dry eye parameters, meibomian glands, and eyebrow position.

NCT ID: NCT05319470 Completed - Glaucoma Clinical Trials

Ocular Surface Disease and IOP Monitoring With Travoprost Without Conservatives

Start date: March 15, 2022
Phase:
Study type: Observational [Patient Registry]

Primary objective of this study is to study the efficacy of travoprost without preservatives in the treatment of glaucoma patients and to monitor the ocular surface.

NCT ID: NCT05247099 Not yet recruiting - Children Clinical Trials

Pediatric Eye Care Investigated Team

PECT
Start date: February 2022
Phase:
Study type: Observational

Use cohort research to analyze and compare eyes of healthy children and children with systemic diseases. Understand and analyze the incidence, characteristics and influencing factors of children's ocular surface diseases. Establish a multi-center children's eye data sharing platform to provide basic data support for the diagnosis and treatment of children's ocular surface diseases.

NCT ID: NCT05195801 Recruiting - Clinical trials for Ocular Surface Disease

Optic Nerve Diameter and Intraocular Pressure Changes in Patients Undergoing Vitrectomy Under General Anesthesia

Start date: January 1, 2022
Phase:
Study type: Observational

This study aimed to measure optic nerve sheath changes in the intraoperative period in patients who underwent vitrectomy surgery and to investigate the intraoperative factors that may affect this. Standard anesthesia protocol will be applied to all patients participating in the study. Optic nerve sheath diameter measurements of the patients taken to the operating room will be made on the operating table by ultrasonography method. Standard anesthesia induction will be performed following SpO2 and ECG monitoring in routine anesthesia monitoring. Depth of anesthesia will be evaluated with routine hemodynamic data.

NCT ID: NCT05145959 Recruiting - Dry Eye Clinical Trials

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

The investigators' aim is to study the effects of mechanical expression of meibomian glands on eyelid disease, ocular surface health in the subacute phase of SJS/TEN. The primary outcome is to use meibomian gland imaging to assess the health and caliber of the meibomian glands of both lower eyelids, between the treated and non-treated eyes before and after the intervention. Monitoring of outcomes will be measured by comparing the results of meibography at the initial visit and at the 6-month follow-up. The secondary outcome assessed will be patient symptoms. The Ocular Surface Disease Index survey will be administered before each treatment and patients will be asked to differentiate their symptoms between the two eyes, both before and after the intervention. The investigators hypothesize that mechanical expression of meibomian glands within the first 6 months of SJS/TEN onset will significantly improve ocular surface disease and symptoms in those patients.

NCT ID: NCT04960696 Completed - Dry Eye Clinical Trials

Effect on Ocular Surface Symptoms of Online Education

Start date: April 14, 2021
Phase:
Study type: Observational [Patient Registry]

retrospective, observational study.

NCT ID: NCT04949295 Completed - Dry Eye Clinical Trials

Evaluation of Ocular Surface in Hemodialysis Patients by Ocular Surface Analyzer

Start date: January 1, 2021
Phase:
Study type: Observational

We clinically observed that some hemodialysis patients had corneal epithelial dryness, shedding, edema, and persistent epithelial nonunion after ocular surgery, which seriously affected the effect of surgery, and it is necessary to study the ocular surface characteristics of hemodialysis patients. In this study, we examined the ocular surface and analyzed and investigated the characteristics of the ocular surface in hemodialysis patients to provide a basis for ocular surface intervention or treatment in hemodialysis patients before ocular surgery in clinical practice.

NCT ID: NCT04918823 Completed - Clinical trials for Ocular Surface Disease

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease

Start date: July 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Secondary endpoints include early (1-month) efficacy data for ocular signs and symptoms.

NCT ID: NCT04828057 Completed - Clinical trials for Primary Open Angle Glaucoma

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Start date: September 1, 2021
Phase:
Study type: Observational

The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline to after 6 months of treatment from initiation, in patients with open angle glaucoma (OAG) or ocular hypertension (OHT), who do not respond sufficiently to initial topical treatment, in routine clinical practice.

NCT ID: NCT04812951 Completed - Clinical trials for Ocular Surface Disease

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery

CSA2020
Start date: February 17, 2021
Phase: Early Phase 1
Study type: Interventional

Use of Cyclosporine 0.1% Eye Drops as Prophylactic Treatment in cataract Surgery